Egfl7 Represses the Vasculogenic Potential of Human Endothelial Progenitor Cells

Overview

Journal Stem Cell Rev Rep

Publisher Springer

Specialty Cell Biology

Date 2017 Oct 6

PMID 28980146

Citations 14

Authors

Clement dAudigier

Sophie Susen

Adeline Blandinieres

Virginie Mattot

Bruno Saubamea

Elisa Rossi

Nathalie Nevo

Severine Lecourt

Coralie L Guerin

Blandine Dizier

Nicolas Gendron

Bertrand Caetano

Pascale Gaussem

Fabrice Soncin

David M Smadja

Affiliations

Soon will be listed here.

Abstract

Egfl7 (VE-statin) is a secreted protein mostly specific to the endothelial lineage during development and in the adult and which expression is enhanced during angiogenesis. Egfl7 involvement in human postnatal vasculogenesis remains unresolved yet. Our aim was to assess Egfl7 expression in several angiogenic cell types originating from human bone marrow, peripheral blood, or cord blood. We found that only endothelial colony forming cells (ECFC), which are currently considered as the genuine endothelial precursor cells, expressed large amounts of Egfl7. In order to assess its potential roles in ECFC, Egfl7 was repressed in ECFC by RNA interference and ECFC angiogenic capacities were tested in vitro and in vivo. Cell proliferation, differentiation, and migration were significantly improved when Egfl7 was repressed in ECFC in vitro, whereas miR-126-3p levels remained unchanged. In vivo, repression of Egfl7 in ECFC significantly improved post-ischemic revascularization in a model of mouse hind-limb ischemia. In conclusion, ECFC are the sole postnatal angiogenic cells which express large amounts of Egfl7 and whose angiogenic properties are repressed by this factor. Thus, Egfl7 inhibition may be considered as a therapeutic option to improve ECFC-mediated postnatal vasculogenesis and to optimize in vitro ECFC expansion in order to develop an optimized cell therapy approach.

Citing Articles

Nestin is a New Partner in Endothelial Colony Forming Cell Angiogenic Potential.

Cras A, Larghero J, Rossi E, Blandinieres A, Gaussem P, Smadja D Stem Cell Rev Rep. 2023; 19(7):2541-2550.

PMID: 37452965 DOI: 10.1007/s12015-023-10587-1.

An increase in elastogenic components in the placental villi of women with chronic venous disease during pregnancy is associated with decreased EGFL7 expression level.

Ortega M, Asunsolo A, Fraile-Martinez O, Sainz F, Saez M, Bravo C Mol Med Rep. 2021; 24(2).

PMID: 34080027 PMC: 8188638. DOI: 10.3892/mmr.2021.12195.

Interleukin-8 Receptors CXCR1 and CXCR2 Are Not Expressed by Endothelial Colony-forming Cells.

Blandinieres A, Hong X, Philippe A, Bieche I, Vacher S, Rossi E Stem Cell Rev Rep. 2020; 17(2):628-638.

PMID: 33185837 PMC: 8337095. DOI: 10.1007/s12015-020-10081-y.

Therapeutic Potential of Endothelial Colony-Forming Cells in Ischemic Disease: Strategies to Improve their Regenerative Efficacy.

Faris P, Negri S, Perna A, Rosti V, Guerra G, Moccia F Int J Mol Sci. 2020; 21(19).

PMID: 33036489 PMC: 7582994. DOI: 10.3390/ijms21197406.

Human endothelial colony-forming cells in regenerative therapy: A systematic review of controlled preclinical animal studies.

Liao G, Zheng K, Shorr R, Allan D Stem Cells Transl Med. 2020; 9(11):1344-1352.

PMID: 32681814 PMC: 7581447. DOI: 10.1002/sctm.20-0141.

References

Durrans A, Stuhlmann H . A role for Egfl7 during endothelial organization in the embryoid body model system. J Angiogenes Res. 2010; 2:4. PMC: 2834644. DOI: 10.1186/2040-2384-2-4. View

Fitch M, Campagnolo L, Kuhnert F, Stuhlmann H . Egfl7, a novel epidermal growth factor-domain gene expressed in endothelial cells. Dev Dyn. 2004; 230(2):316-24. PMC: 1458501. DOI: 10.1002/dvdy.20063. View

Johnson L, Huseni M, Smyczek T, Lima A, Yeung S, Cheng J . Anti-EGFL7 antibodies enhance stress-induced endothelial cell death and anti-VEGF efficacy. J Clin Invest. 2013; 123(9):3997-4009. PMC: 3754254. DOI: 10.1172/JCI67892. View

Smadja D, Bieche I, Emmerich J, Aiach M, Gaussem P . PAR-1 activation has different effects on the angiogenic activity of endothelial progenitor cells derived from human adult and cord blood. J Thromb Haemost. 2006; 4(12):2729-31. DOI: 10.1111/j.1538-7836.2006.02208.x. View

He T, Peterson T, Holmuhamedov E, Terzic A, Caplice N, Oberley L . Human endothelial progenitor cells tolerate oxidative stress due to intrinsically high expression of manganese superoxide dismutase. Arterioscler Thromb Vasc Biol. 2004; 24(11):2021-7. DOI: 10.1161/01.ATV.0000142810.27849.8f. View

Smadja D, Bieche I, Silvestre J, Germain S, Cornet A, Laurendeau I . Bone morphogenetic proteins 2 and 4 are selectively expressed by late outgrowth endothelial progenitor cells and promote neoangiogenesis. Arterioscler Thromb Vasc Biol. 2008; 28(12):2137-43. DOI: 10.1161/ATVBAHA.108.168815. View

Yoder M, Mead L, Prater D, Krier T, Mroueh K, Li F . Redefining endothelial progenitor cells via clonal analysis and hematopoietic stem/progenitor cell principals. Blood. 2006; 109(5):1801-9. PMC: 1801067. DOI: 10.1182/blood-2006-08-043471. View

Smadja D, Bieche I, Susen S, Mauge L, Laurendeau I, dAudigier C . Interleukin 8 is differently expressed and modulated by PAR-1 activation in early and late endothelial progenitor cells. J Cell Mol Med. 2008; 13(8B):2534-2546. PMC: 6512392. DOI: 10.1111/j.1582-4934.2008.00429.x. View

Papaioannou D, Shen C, Nicolet D, McNeil B, Bill M, Karunasiri M . Prognostic and biological significance of the proangiogenic factor EGFL7 in acute myeloid leukemia. Proc Natl Acad Sci U S A. 2017; 114(23):E4641-E4647. PMC: 5468639. DOI: 10.1073/pnas.1703142114. View

10.

Huang C, Li X, Zhou Y, Luo Y, Li C, Yuan X . Expression and clinical significance of EGFL7 in malignant glioma. J Cancer Res Clin Oncol. 2010; 136(11):1737-43. DOI: 10.1007/s00432-010-0832-9. View

11.

Smadja D, Basire A, Amelot A, Conte A, Bieche I, Le Bonniec B . Thrombin bound to a fibrin clot confers angiogenic and haemostatic properties on endothelial progenitor cells. J Cell Mol Med. 2008; 12(3):975-86. PMC: 4401136. DOI: 10.1111/j.1582-4934.2008.00161.x. View

12.

Poissonnier L, Villain G, Soncin F, Mattot V . Egfl7 is differentially expressed in arteries and veins during retinal vascular development. PLoS One. 2014; 9(3):e90455. PMC: 3942447. DOI: 10.1371/journal.pone.0090455. View

13.

Foubert P, Silvestre J, Souttou B, Barateau V, Martin C, Ebrahimian T . PSGL-1-mediated activation of EphB4 increases the proangiogenic potential of endothelial progenitor cells. J Clin Invest. 2007; 117(6):1527-37. PMC: 1866248. DOI: 10.1172/JCI28338. View

14.

Soncin F, Mattot V, Lionneton F, Spruyt N, Lepretre F, Begue A . VE-statin, an endothelial repressor of smooth muscle cell migration. EMBO J. 2003; 22(21):5700-11. PMC: 275406. DOI: 10.1093/emboj/cdg549. View

15.

Battle T, Arnal J, Challah M, Michel J . Selective isolation of rat aortic wall layers and their cell types in culture--application to converting enzyme activity measurement. Tissue Cell. 1994; 26(6):943-55. DOI: 10.1016/0040-8166(94)90043-4. View

16.

Reny J, Laurendeau I, Fontana P, Bieche I, Dupont A, Remones V . The TF-603A/G gene promoter polymorphism and circulating monocyte tissue factor gene expression in healthy volunteers. Thromb Haemost. 2004; 91(2):248-54. DOI: 10.1160/TH03-09-0566. View

17.

Chim S, Kuek V, Chow S, Lim B, Tickner J, Zhao J . EGFL7 is expressed in bone microenvironment and promotes angiogenesis via ERK, STAT3, and integrin signaling cascades. J Cell Physiol. 2014; 230(1):82-94. DOI: 10.1002/jcp.24684. View

18.

Wang S, Aurora A, Johnson B, Qi X, McAnally J, Hill J . The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis. Dev Cell. 2008; 15(2):261-71. PMC: 2685763. DOI: 10.1016/j.devcel.2008.07.002. View

19.

Garcia-Carbonero R, Van Cutsem E, Rivera F, Jassem J, Gore Jr I, Tebbutt N . Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First-Line Metastatic Colorectal Cancer. Oncologist. 2017; 22(4):375-e30. PMC: 5388369. DOI: 10.1634/theoncologist.2016-0133. View

20.

Hu M, Ma C, Wang X, Ye C, Zhang G, Chen L . MicroRNA-126 inhibits tumor proliferation and angiogenesis of hepatocellular carcinoma by down-regulating EGFL7 expression. Oncotarget. 2016; 7(41):66922-66934. PMC: 5341847. DOI: 10.18632/oncotarget.11877. View